TPW 7.14 When Weight Loss Hurts: An Observational Study of Emerging Biliary and Pancreatic Complications in Patients Receiving Tirzepatide (Mounjaro)
British Journal of Surgery · 05.08.2026 · 113 (Supplement_8)
DOI: 10.1093/bjs/znag087.383 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 05.08.2026. Verfasst von Bidisha Singha und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Aim
The study aims to interpret whether Tirzepatide (Mounjaro) use is associated with an increased risk of precipitating cholecystitis or pancreatitis in patients receiving GLP-1 therapy.
Methods
A single-cycle prospective audit was conducted over a seven-month period, reviewing patients receiving Tirzepatide (Mounjaro) who presented with abdominal pain. Data collected comprised patient age, gender, presence of type 2 diabetes mellitus, and current use of tirzepatide (Mounjaro). A second cycle is required to further explore and confirm the initial findings.
Results
The first audit cycle included 30 patients receiving the GLP-1 receptor agonist tirzepatide (Mounjaro) who presented with abdominal pain in the last 7 months. Five were male (16.7%), and 25 female (83.3%; female: male 5:1). The cohort was predominantly middle-aged: 12 patients (40.0%) were aged 21- 40 years and 14 (46.7%) were 41- 60 years, meaning 26 patients (86.7%) fell within the 21- 60 year age range. Four patients (13.3%) were aged 61–80 years. Six patients (20.0%) had type 2 diabetes, while 24 (80.0%) did not. Biliary or pancreatic pathology was identified in 15 patients (50.0%). New-onset biliary colic (n=8 ) was more frequent than exacerbation of gallstone disease (5 cases; ratio 1.6:1). Biliary-only disease (n = 13) greatly exceeded pancreatic involvement (2 cases; ratio 6.5:1). New-onset biliary colic accounted for 53.3% of pathology cases (26.7% overall). These findings show a strong signal of biliary pathology in the cohort.
Conclusion
Mounjaro use may be linked to abdominal pathology, particularly biliary colic, warranting the need for rigorous analysis.
Zitieren
APA
Singha, B., Okkeh, O., & Nahid, M. A. K. (2026). TPW 7.14 When Weight Loss Hurts: An Observational Study of Emerging Biliary and Pancreatic Complications in Patients Receiving Tirzepatide (Mounjaro). British Journal of Surgery, 113(Supplement_8). https://doi.org/10.1093/bjs/znag087.383
Vancouver
Singha B, Okkeh O, Nahid MAK. TPW 7.14 When Weight Loss Hurts: An Observational Study of Emerging Biliary and Pancreatic Complications in Patients Receiving Tirzepatide (Mounjaro). British Journal of Surgery. 2026;113(Supplement_8). doi:10.1093/bjs/znag087.383
BibTeX
@article{Singha2026,
author = {Singha, Bidisha and Okkeh, Omar and Nahid, Md Abu Kamal},
title = {TPW 7.14 When Weight Loss Hurts: An Observational Study of Emerging Biliary and Pancreatic Complications in Patients Receiving Tirzepatide (Mounjaro)},
journal = {British Journal of Surgery},
year = {2026},
volume = {113},
number = {Supplement_8},
doi = {10.1093/bjs/znag087.383}
}
EUVIMED